Researchers Seek Volunteers To Test Anthrax Vaccine
BALTIMORE -- The Johns Hopkins Bloomberg School of Public Health is testing a new vaccine that researchers hope will aid in preventing anthrax.
A synthetic protein and aluminum hydroxide comprise the vaccine, developed by VaxGen Inc., that health officials hope will encourage immune response. The formula will be given in different combinations to 480 healthy volunteers.
The vaccine is base on research conducted by the U.S. Army Medical Research Institute of Infectious Diseases. The study is funded by an $80.3 million contract from the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
Hopkins is looking for volunteers to take part in the anthrax vaccine trial. Those interested may be able to participate by calling the school, dial: (410) 614-9702.
A synthetic protein and aluminum hydroxide comprise the vaccine, developed by VaxGen Inc., that health officials hope will encourage immune response. The formula will be given in different combinations to 480 healthy volunteers.
The vaccine is base on research conducted by the U.S. Army Medical Research Institute of Infectious Diseases. The study is funded by an $80.3 million contract from the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
Hopkins is looking for volunteers to take part in the anthrax vaccine trial. Those interested may be able to participate by calling the school, dial: (410) 614-9702.
